Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up
Rhinology Journal · 01.06.2024 · 0-0
DOI: 10.4193/rhin23.278 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Rhinology Journal, online erschienen am 01.06.2024. Verfasst von A Kiricsi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Albert Szent-Gyorgyi Health Center, University of Szeged, Department of Otorhinolaryngology, Head. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Sinusitis, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Research on the immune mechanism behind chronic rhinosinusitis (CRS) has revealed various new endotypes, leading to targeted therapies, especially for severe uncontrolled CRS. Biologics are novel therapeutic strategies providing targeted treatment for the difficult-to-treat recalcitrant CRSwNP patients. Dupilumab is a fully human-derived monoclonal antibody that binds to IL4Rα, inhibiting the signalling of both IL-4 and IL-13. In Hungary, it is approved for the treatment of uncontrolled CRSwNP according to criteria based on the EPOS2020 and the Hungarian guidelines. Methodology: This study aimed to collect and evaluate real-world therapeutic data of CRSwNP patients treated with dupilumab. One hundred thirty-five patients from eight different referral centres have been enrolled in this study, who received dupilumab since 2020. All subjects were adult patients (>18 years) with uncontrolled CRSwNP. Baseline data collection included demographics, medical history, previous surgeries, related comorbidities, total endoscopic nasal polyp score (NPS), SNOT22, nasal congestion parameters measured with visual analogue scale (VAS) and nasal obstruction evaluation scale (NOSE), loss of smell score (LSS) and eosinophil count. 300 mg dupilumab was administered subcutaneously every second week. Follow up visits were performed after 6 and 12 months.
Results
After 6 and 12 months of treatment significant improvement was detected in all clinical parameters. Safety was proved, no severe side effects occurred, and no rescue treatment was necessary.
Conclusions
Our real-life findings show that continuous dupilumab treatment is effective and safe in daily clinical practice in CRSwNP and other type 2 comorbidities such as bronchial asthma and NERD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Albert Szent-Gyorgyi Health Center, University of Szeged, Department of Otorhinolaryngology, Head.
- Semmelweis University, Department of Otorhinolaryngology, Head and Neck Surgery, Budapest, Hungary.
- St. John's Hospital, Department of Otorhinolaryngology and Maxillofacial Surgery, Budapest, Hungary.
- Hospital Peterfy Sandor Str, Otorhinolaryngology, Head and Neck Surgery, Budapest, Hungary, Budapest Hungary.
- Hospital of the Hungarian Army, Department of Otorhinolaryngology, Head and Neck Surgery, Budapest, Hungary.
- University of Pecs, Department of Otorhinolaryngology, Head and Neck Surgery, Pecs, Hungary.
Zitieren
APA
Kiricsi, A., Bella, Z., Kraxner, H., Szaloki, T., Fent, Z., Liktor, B., Huszka, J., Laszlo, P., Gobol, D., Helfferich, F., Vaska, Z., Piski, Z., Juhasz-Loisch, L., Horvath, B., Galantai, G., Krisztin, N., Toth, L., Bodi, A., Matuz, M., …, & Hirschberg, A. (2024). Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up. Rhinology Journal, 0(0), 0-0. https://doi.org/10.4193/rhin23.278
Vancouver
Kiricsi A, Bella Z, Kraxner H, Szaloki T, Fent Z, Liktor B, et al. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up. Rhinology Journal. 2024;0(0):0-0. doi:10.4193/rhin23.278
BibTeX
@article{Kiricsi2024,
author = {Kiricsi, A and Bella, Z and Kraxner, H and Szaloki, T and Fent, Z and Liktor, B and Huszka, J and Laszlo, P and Gobol, D and Helfferich, F and Vaska, Z and Piski, Z and Juhasz-Loisch, L and Horvath, B and Galantai, G and Krisztin, N and Toth, L and Bodi, A and Matuz, M and Lujber, L and Hirschberg, A},
title = {Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up},
journal = {Rhinology Journal},
year = {2024},
volume = {0},
number = {0},
pages = {0--0},
doi = {10.4193/rhin23.278}
}
EUVIMED